Energenesis Biomedical Co (TPE:6657) Research & Development: NT$194.43 Mil (TTM As of Dec. 2025)


TPE:6657 Energenesis Biomedical Co Ltd TPE:6657
64 GF Score
Price NT$34.90
GF Value NT$51.28
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Energenesis Biomedical Co Research & Development?

Energenesis Biomedical Co TPE:6657 -2.92% 64 Research & Development is NT$194.43 Mil as of Dec. 2025. GuruFocus rates TPE:6657 with a GF Score™ of 64/100 and a GF Value™ of NT$51.28 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Energenesis Biomedical Co's Research & Development for the three months ended in Dec. 2025 was NT$47.52 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$194.43 Mil.

Energenesis Biomedical Co  (TPE:6657) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Energenesis Biomedical Co Research & Development Related Terms

Energenesis Biomedical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Energenesis Biomedical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Energenesis Biomedical Co Research & Development Chart

Energenesis Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.76 213.68 185.13 179.85 194.43

Energenesis Biomedical Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.47 79.92 33.45 33.55 47.52
TPE:6657
64GF Score
Energenesis Biomedical Co Ltd TPE:6657
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Energenesis Biomedical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$194.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$194.43 Mil mean?
Energenesis Biomedical Co (TPE:6657) has a Research & Development of NT$194.43 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Energenesis Biomedical Co and its competitors.
Is Energenesis Biomedical Co's Research & Development too high?
Energenesis Biomedical Co's current Research & Development is NT$194.43 Mil. Overall, Energenesis Biomedical Co has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Research & Development compare to VRTX and REGN?
Energenesis Biomedical Co's Research & Development of NT$194.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Energenesis Biomedical Co and its competitors. Energenesis Biomedical Co's current Research & Development is NT$194.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.28, compared to a current price of NT$34.90 — trading 31.9% below its estimated fair value. The current Research & Development is NT$194.43 Mil. Energenesis Biomedical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Research & Development is NT$194.43 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?

Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued. The current stock price of NT$34.90 is trading 31.9% below its estimated GF Value™ of NT$51.28. GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.

Key valuation signals for TPE:6657:

  • Research & Development: NT$194.43 Mil
  • GF Value™: NT$51.28 vs. price of NT$34.90 (31.9% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Energenesis Biomedical Co Business Description

Address No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score

Get the complete analysis for TPE:6657

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.90
Price
NT$51.28
GF Value